ReviewFrontiers in pharmacology2019
Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis.
Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains.Frontiers in medicine · 2020Pooled it
- Impact of Biologics on Comorbidities in Patients with Psoriasis or Psoriatic Arthritis.Biomedicines · 2025Article
- Recent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases.Frontiers in pharmacology · 2024Review
- Serum IL-23 significantly decreased in obese patients with psoriatic arthritis six months after a structured weight loss intervention.Arthritis research & therapy · 2023Article
- Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors.Inflammopharmacology · 2023Review
- Neutrophil breaching of the blood vessel pericyte layer during diapedesis requires mast cell-derived IL-17A.Nature communications · 2022Article
- Acute joint swelling in psoriatic arthritis: Flare or "psout"-A 10-year-monocentric study on synovial fluid.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.Annals of the rheumatic diseases · 2022Observational
- Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.Clinical rheumatology · 2021Article
- Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.Annals of the rheumatic diseases · 2021Observational
- Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches.Biomedicines · 2021Review
- IL-23 orchestrating immune cell activation in arthritis.Rheumatology (Oxford, England) · 2021Article
- Local Defence System in Healthy Lungs.Clinics and practice · 2021Article
- Role of Janus Kinase Inhibitors in Therapy of Psoriasis.Journal of clinical medicine · 2021Review
- Chromatin Looping Links Target Genes with Genetic Risk Loci for Dermatological Traits.The Journal of investigative dermatology · 2021Article
- IBDDB: a manually curated and text-mining-enhanced database of genes involved in inflammatory bowel disease.Database : the journal of biological databases and curation · 2021Article
- Lessons on SpA pathogenesis from animal models.Seminars in immunopathology · 2021Review
- Article
- Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357.ACS medicinal chemistry letters · 2021Article
- A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease. Interleukin (IL)-17 plays a major role in the development of both psoriasis and PsA. IL-23 is important in the proliferation and maintenance of IL-17, and therefore, cytokines of the IL-23/IL-17 axis attracted much interest as therapeutic targets in psoriasis and PsA. Therapeutic agents targeting the IL-23/IL-17 axis have been proven to be very effective in psoriasis and PsA, some are already in the therapeutic armamentarium and others are in the development. Some agents, target IL-23 and others IL-17 and include anti-IL-12/IL-23 p40 (ustekinumab, briankizumab), anti-IL-23p19 (guselkumab, tildrakizumab, risankizumab, brazikumab, mirikizumab), anti-IL-17A (secukinumab, ixekizumab), dual anti-IL-17A and anti-IL-17F (bimekizumab), or anti-IL-17 receptor (brodalumab) monoclonal antibodies. Janus tyrosine kinase(JAK) inhibitors also directly affect IL-23 and, thus, IL-17. After the first-generation pan-JAK inhibitors have been shown efficacy (tofacitinib, baricitinib), new-generation selective JAK inhibitors (filgotinib, upadacitinib) are under investigation in psoriasis and PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.